Amy Rhoden Smith, PhD

Gene Therapy Development Leader

Amy is a part of the Development team at Precision BioSciences, where she leads in vivo gene editing therapeutic programs into preclinical development. In her role, Amy works with and brings together teams across Precision. Through her previous positions at Boston-based Moderna and Intellia Therapeutics, Amy has experience in CRISPR/Cas9 gene editing, mRNA, and oligonucleotide therapeutic modalities as well as lipid nanoparticle (LNP) delivery systems for these modalities. She received her PhD in Organic Chemistry from the University of Texas at Austin and her BS in Chemistry from College of Charleston. A Georgia native, Amy is enjoying being relocated back to the South and the warmer weather. She and her chef husband are excited to explore the Durham restaurant scene and they are always on the lookout for friends who like to play board games!